Skip to main content
Erschienen in: Der Ophthalmologe 11/2013

01.11.2013 | CME Zertifizierte Fortbildung

Update endokrine Orbitopathie

verfasst von: Prof. Dr. A. Eckstein, U. Berchner-Pfannschmidt, D. Führer, J. Esser

Erschienen in: Die Ophthalmologie | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei der endokrinen Orbitopathie handelt es sich um eine Autoimmunerkrankung der Bindegewebe der okulären Adnexe, die meist zusammen mit einer Autoimmunthyreopathie vom Typ Basedow auftritt. Spezifisch ist das Auftreten von Anti-TSH-Rezeptor-Antikörpern, deren Spiegel mit dem Verlauf sowohl der Orbita- als auch der Schilddrüsenerkrankung assoziiert sind. Einer akuten entzündlichen Phase folgt ein Stadium der Defektheilung. Hervortretende Augen, Doppelbildwahrnehmung und Oberlidretraktion sowie die Entzündungssymptome können die Lebensqualität der Patienten erheblich beeinträchtigen. Als antientzündliche Maßnahmen stehen i.v.-Steroide, „off label“ eine immunsuppressive Therapie und eine Selensupplementation oder auch eine notfallmäßige Orbitadekompression zur Verfügung. Im inaktiven Stadium können Exophthalmus, Augenbewegungsstörungen und Lidfehlstellungen durch operative Maßnahmen wie Orbitadekompression, Augenmuskelrücklagerungen und Lidchirurgie erfolgreich korrigiert werden.
Literatur
1.
Zurück zum Zitat Iyer S, Bahn R (2012) Immunopathogenesis of Graves‘ ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab 26(3):281–289PubMedCrossRef Iyer S, Bahn R (2012) Immunopathogenesis of Graves‘ ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab 26(3):281–289PubMedCrossRef
2.
Zurück zum Zitat Smith TJ, Hegedus L, Douglas RS (2012) Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves‘ orbitopathy. Best Pract Res Clin Endocrinol Metab 26(3):291–302PubMedCrossRef Smith TJ, Hegedus L, Douglas RS (2012) Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves‘ orbitopathy. Best Pract Res Clin Endocrinol Metab 26(3):291–302PubMedCrossRef
3.
Zurück zum Zitat Eckstein AK et al (2009) Current insights into the pathogenesis of Graves‘ orbitopathy. Horm Metab Res 41(6):456–464PubMedCrossRef Eckstein AK et al (2009) Current insights into the pathogenesis of Graves‘ orbitopathy. Horm Metab Res 41(6):456–464PubMedCrossRef
4.
Zurück zum Zitat Smith TJ (2010) Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy. Clin Exp Immunol 162(1):24–31PubMedCrossRef Smith TJ (2010) Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy. Clin Exp Immunol 162(1):24–31PubMedCrossRef
5.
Zurück zum Zitat Mourits MP et al (1997) Clinical activity score as a guide in the management of patients with Graves‘ ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9–14 Mourits MP et al (1997) Clinical activity score as a guide in the management of patients with Graves‘ ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9–14
6.
Zurück zum Zitat Eckstein A et al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetric Graves ophthalmopathy. Br J Ophthalmol 93:1052–1056PubMedCrossRef Eckstein A et al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetric Graves ophthalmopathy. Br J Ophthalmol 93:1052–1056PubMedCrossRef
7.
Zurück zum Zitat Perros P, Kendall-Taylor P (1998) Natural history of thyroid eye disease. Thyroid 8(5):423–425PubMedCrossRef Perros P, Kendall-Taylor P (1998) Natural history of thyroid eye disease. Thyroid 8(5):423–425PubMedCrossRef
8.
Zurück zum Zitat Bartalena L et al (2008) Consensus statement of the European Group on Graves‘ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273–285PubMedCrossRef Bartalena L et al (2008) Consensus statement of the European Group on Graves‘ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273–285PubMedCrossRef
9.
Zurück zum Zitat Marcocci C et al (2011) Selenium and the course of mild Graves‘ orbitopathy. N Engl J Med 364(20):1920–1931PubMedCrossRef Marcocci C et al (2011) Selenium and the course of mild Graves‘ orbitopathy. N Engl J Med 364(20):1920–1931PubMedCrossRef
10.
Zurück zum Zitat Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: Intravenous glucocorticoids for Graves‘ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320–332PubMedCrossRef Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: Intravenous glucocorticoids for Graves‘ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320–332PubMedCrossRef
11.
Zurück zum Zitat Bartalena L et al (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves‘ orbitopathy. J Clin Endocrinol Metab 97(12):4454–4463PubMedCrossRef Bartalena L et al (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves‘ orbitopathy. J Clin Endocrinol Metab 97(12):4454–4463PubMedCrossRef
12.
Zurück zum Zitat Mourits MP et al (2000) Radiotherapy for Graves‘ orbitopathy: randomised placebo-controlled study. Lancet 355(9214):1505–1509PubMedCrossRef Mourits MP et al (2000) Radiotherapy for Graves‘ orbitopathy: randomised placebo-controlled study. Lancet 355(9214):1505–1509PubMedCrossRef
13.
Zurück zum Zitat Terwee CB et al (2005) Measuring disease activity to predict therapeutic outcome in Graves‘ ophthalmopathy. Clin Endocrinol (Oxf) 62(2):145–155 Terwee CB et al (2005) Measuring disease activity to predict therapeutic outcome in Graves‘ ophthalmopathy. Clin Endocrinol (Oxf) 62(2):145–155
14.
Zurück zum Zitat Garrity JA et al (1993) Results of transantral orbital decompression in 428 patients with severe Graves‘ ophthalmopathy. Am J Ophthalmol 116(5):533–547PubMed Garrity JA et al (1993) Results of transantral orbital decompression in 428 patients with severe Graves‘ ophthalmopathy. Am J Ophthalmol 116(5):533–547PubMed
15.
Zurück zum Zitat Salvi M et al (2007) Treatment of Graves‘ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156(1):33–40PubMedCrossRef Salvi M et al (2007) Treatment of Graves‘ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156(1):33–40PubMedCrossRef
16.
Zurück zum Zitat Wabbels B, Forl M (2007) Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction. Ophthalmologe 104(9):771–776PubMedCrossRef Wabbels B, Forl M (2007) Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction. Ophthalmologe 104(9):771–776PubMedCrossRef
17.
Zurück zum Zitat Lazarus JH (2012) Epidemiology of Graves‘ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 26(3):273–279PubMedCrossRef Lazarus JH (2012) Epidemiology of Graves‘ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 26(3):273–279PubMedCrossRef
18.
Zurück zum Zitat Eckstein A et al (2009) Role of TSH receptor autoantibodies for the diagnosis of Graves‘ disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the thyroid section of the German Society of Endocrinology. Med Klin (Munich) 104(5):343–348 Eckstein A et al (2009) Role of TSH receptor autoantibodies for the diagnosis of Graves‘ disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the thyroid section of the German Society of Endocrinology. Med Klin (Munich) 104(5):343–348
19.
Zurück zum Zitat Eckstein AK et al (2007) Patients with severe Graves‘ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 67(4):607–612 Eckstein AK et al (2007) Patients with severe Graves‘ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 67(4):607–612
20.
Zurück zum Zitat Bartalena L (2011) The dilemma of how to manage Graves‘ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96(3):592–599PubMedCrossRef Bartalena L (2011) The dilemma of how to manage Graves‘ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96(3):592–599PubMedCrossRef
21.
Zurück zum Zitat Eckstein A, Schittkowski M, Esser J (2012) Surgical treatment of Graves‘ ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26(3):339–358PubMedCrossRef Eckstein A, Schittkowski M, Esser J (2012) Surgical treatment of Graves‘ ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26(3):339–358PubMedCrossRef
22.
Zurück zum Zitat Verity DH, Rose GE (2013) Acute thyroid eye disease (TED): principles of medical and surgical management. Eye 27(3):308–319PubMedCrossRef Verity DH, Rose GE (2013) Acute thyroid eye disease (TED): principles of medical and surgical management. Eye 27(3):308–319PubMedCrossRef
23.
Zurück zum Zitat Baldeschi L (2010) Small versus coronal incision orbital decompression in Graves‘ orbitopathy. Orbit 29(4):177–182PubMedCrossRef Baldeschi L (2010) Small versus coronal incision orbital decompression in Graves‘ orbitopathy. Orbit 29(4):177–182PubMedCrossRef
24.
Zurück zum Zitat Baldeschi L et al (2005) The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia. Am J Ophthalmol 140(4):642–647PubMedCrossRef Baldeschi L et al (2005) The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia. Am J Ophthalmol 140(4):642–647PubMedCrossRef
25.
Zurück zum Zitat Kalpadakis P et al (2004) Muscle surgery in patients with Graves‘ disease using topical anesthesia. Ophthalmology 111(8):1563–1568PubMedCrossRef Kalpadakis P et al (2004) Muscle surgery in patients with Graves‘ disease using topical anesthesia. Ophthalmology 111(8):1563–1568PubMedCrossRef
26.
Zurück zum Zitat Esser J, Eckstein A (1999) Ocular muscle and eyelid surgery in thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 107(Suppl 5):S214–S221PubMedCrossRef Esser J, Eckstein A (1999) Ocular muscle and eyelid surgery in thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 107(Suppl 5):S214–S221PubMedCrossRef
27.
Zurück zum Zitat Esser J, Schittkowski M, Eckstein A (2011) Graves‘ orbitopaty: inferior rectus tendon elongation for large vertical squint angles that cannot be corrected by simple muscle recession. Klin Monatsbl Augenheilkd 228(10):880–886PubMedCrossRef Esser J, Schittkowski M, Eckstein A (2011) Graves‘ orbitopaty: inferior rectus tendon elongation for large vertical squint angles that cannot be corrected by simple muscle recession. Klin Monatsbl Augenheilkd 228(10):880–886PubMedCrossRef
28.
Zurück zum Zitat Neoh C, Eckstein A (2010) Eyelid surgery. In: Wiersinga WM, Kahaly GJ (Hrsg) Graves‘ orbitopathy: a multidisciplinary approach – questions and answers. Karger, Basel, S 200–210 Neoh C, Eckstein A (2010) Eyelid surgery. In: Wiersinga WM, Kahaly GJ (Hrsg) Graves‘ orbitopathy: a multidisciplinary approach – questions and answers. Karger, Basel, S 200–210
29.
Zurück zum Zitat Mourits MP, Koornneef L (1991) Lid lengthening by sclera interposition for eyelid retraction in Graves‘ ophthalmopathy. Br J Ophthalmol 75(6):344–347PubMedCrossRef Mourits MP, Koornneef L (1991) Lid lengthening by sclera interposition for eyelid retraction in Graves‘ ophthalmopathy. Br J Ophthalmol 75(6):344–347PubMedCrossRef
30.
Zurück zum Zitat Eckstein A, Esser J (2011) A temporal tarsorrhaphy increases the effect of lower lid lengthening in patients with Graves‘ orbitopathy. Klin Monatsbl Augenheilkd 228(10):887–891PubMedCrossRef Eckstein A, Esser J (2011) A temporal tarsorrhaphy increases the effect of lower lid lengthening in patients with Graves‘ orbitopathy. Klin Monatsbl Augenheilkd 228(10):887–891PubMedCrossRef
Metadaten
Titel
Update endokrine Orbitopathie
verfasst von
Prof. Dr. A. Eckstein
U. Berchner-Pfannschmidt
D. Führer
J. Esser
Publikationsdatum
01.11.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Ophthalmologie / Ausgabe 11/2013
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-013-2976-x

Weitere Artikel der Ausgabe 11/2013

Der Ophthalmologe 11/2013 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.